OncoZenge AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	1.29	3.86	12.63	29.14	51.22	10
Cash & Short-Term Investments	1.29	3.86	12.63	29.14	51.22	10
Cash Growth	-86.61%	-69.41%	-56.67%	-43.11%	412.23%	-
Other Receivables	0.61	0.52	0.64	0.71	0.85	5.51
Receivables	3.32	0.52	0.64	0.71	0.85	5.51
Prepaid Expenses	0.28	0.2	0.22	0.19	0.06	-
Total Current Assets	4.89	4.58	13.49	30.04	52.13	15.51
Other Intangible Assets	6.85	6.85	6.85	6.85	6.85	22.05
Long-Term Deferred Tax Assets	-	-	-	-	3.08	0.73
Long-Term Deferred Charges	-	-	-	-	23.17	-
Total Assets	11.74	11.43	20.34	36.89	85.23	38.3
Accounts Payable	0.71	0.66	0.93	1.65	4.02	-
Accrued Expenses	1	0.78	0.66	1.01	0.5	2.8
Other Current Liabilities	0.05	0.05	0.11	0.26	0.39	6.21
Total Current Liabilities	1.75	1.48	1.7	2.92	4.9	9.01
Total Liabilities	1.75	1.48	1.7	2.92	4.9	9.01
Common Stock	1.3	1.3	1.3	1.3	1.3	0.5
Additional Paid-In Capital	84.41	84.41	84.41	83.84	83.54	29.32
Retained Earnings	-75.72	-75.76	-67.07	-51.17	-4.52	-0.64
Comprehensive Income & Other	-	-	-	-	-	0.1
Shareholders' Equity	9.99	9.95	18.64	33.97	80.32	29.28
Total Liabilities & Equity	11.74	11.43	20.34	36.89	85.23	38.3
Net Cash (Debt)	1.29	3.86	12.63	29.14	51.22	10
Net Cash Growth	-86.61%	-69.41%	-56.67%	-43.11%	412.23%	-
Net Cash Per Share	0.11	0.33	1.08	2.49	4.35	-
Filing Date Shares Outstanding	11.71	11.71	11.71	11.71	11.71	-
Total Common Shares Outstanding	11.71	11.71	11.71	11.71	11.71	-
Working Capital	3.14	3.1	11.79	27.12	47.23	6.5
Book Value Per Share	0.85	0.85	1.59	2.90	6.86	-
Tangible Book Value	3.14	3.1	11.79	27.12	73.47	7.23
Tangible Book Value Per Share	0.27	0.26	1.01	2.32	6.27	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.